In the last 25 years, Prostate Specific Antigen （PSA） screening has resulted ina large gap between the likelihood of being diagnosed with and of dying of prostate cancer, leading to the clinical problems of overdiag...In the last 25 years, Prostate Specific Antigen （PSA） screening has resulted ina large gap between the likelihood of being diagnosed with and of dying of prostate cancer, leading to the clinical problems of overdiagnosis and overtreatment. Despite the favorable outcomes reported for active surveil- lance, its clinical use is limited, with 〉90% of men in the US diagnosed with potentially indol- ent disease undergoing immediate treatment with radiation or surgery. We have designed a novel strategy of molecular profiling of prostate cancers, allowing an assessment of tumor aggres- siveness to be based on tumor tissue obtained at biopsy.展开更多
文摘In the last 25 years, Prostate Specific Antigen （PSA） screening has resulted ina large gap between the likelihood of being diagnosed with and of dying of prostate cancer, leading to the clinical problems of overdiagnosis and overtreatment. Despite the favorable outcomes reported for active surveil- lance, its clinical use is limited, with 〉90% of men in the US diagnosed with potentially indol- ent disease undergoing immediate treatment with radiation or surgery. We have designed a novel strategy of molecular profiling of prostate cancers, allowing an assessment of tumor aggres- siveness to be based on tumor tissue obtained at biopsy.
